

# **Bijlage : Referenties / Bronnen**

## Inleiding

### **Studie waaruit blijkt dat kinderen NIET bijdragen tot de verspreiding van Sars-Cov-2**

1. Ludvigsson, J. F. (2020). Children are unlikely to be the main drivers of the COVID-19 pandemic - A systematic review. *Acta paediatrica (Oslo, Norway: 1992)*, 109(8), 1525-1530.

### **Studies die een significante stijging tonen in smetvrees, compulsief hygiënisch handelen en het ontwikkelen van neurotisch gedrag bij jonge kinderen en adolescenten door de corona- crisis en de corona- maatregelen**

2. Tanir Y, Karayagmurlu A, Kaya İ, et al. Exacerbation of obsessive compulsive disorder symptoms in children and adolescents during COVID-19 pandemic. *Psychiatry Research* 2020; **293**.

3. Aleksandrov D, Okhrimenko I. Psychological Risk Factors of the Neurotization of Adolescents under the Conditions of Quarantine Measures of the COVID-19 Epidemic. *BRAIN: Broad Research in Artificial Intelligence & Neuroscience* 2020; **11**: 29-36.

### **Over de exponentiële toename (50%) van het aantal depressies, angststoornissen, Post-Traumatisch Stress Syndroom (PTSD) en slaapproblemen en de enorme toename van het aantal zelfmoordneigingen (38 %) en zelfmoordpogingen.**

4. Murata S, Rezeppa T, Thoma B, et al. The psychiatric sequelae of the COVID-19 pandemic in adolescents, adults, and health care workers. *Depression & Anxiety (1091-4269)* 2021; **38**(2): 233-46.

### **Bewijs dat stress-factoren dragen bij tot verminderde immuniteit en zelfs tot verminderde vaccinatie-efficiëntie binnen bepaalde doelgroepen**

5. Hayward SE, Dowd JB, Fletcher H, Nellums LB, Wurie F, Boccia D. A systematic review of the impact of psychosocial factors on immunity: Implications for enhancing BCG response against tuberculosis. *SSM - Population Health* 2020; **10**.

6. Schakel L, Veldhuijzen Dieuwke S, Crompvoets Paige I, et al. Effectiveness of Stress-Reducing Interventions on the Response to Challenges to the Immune System: A Meta-Analytic Review. *Psychotherapy & Psychosomatics* 2019; **88**(5): 274-86.

### **Over bewijs dat afname van de Psycho-neuro- immuniteit door langdurige stress zal op termijn leiden tot een toename in het aantal zieken met chronisch inflammatoire en langdurige psychologische ziektebeelden**

7. Johnson D, Dupuis G, Piche J, Clayborne Z, Colman I. Adult mental health outcomes of adolescent depression: A systematic review. *Depression & Anxiety (1091-4269)* 2018; **35**(8): 700-16.

## Deel 1.

1\* E.H.R.M., S.A.S. / Frankrijk, 1 juli 2014

2\* E.H.R.M. 24 mei 2005, appl. nr. 45214/99 (Sildedzis t. Polen), § 48: "(...) the Court is of the opinion that the legal provisions concerned lacked the required clarity and precision necessary to provide adequate protection against arbitrary interference by the public authorities with the right to the peaceful enjoyment of the applicant's possessions."

(\*) The infection fatality rate of COVID-19 inferred from seroprevalence data by John P.A. Ioannidis - Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA

(<https://pubmed.ncbi.nlm.nih.gov/33716331/>).

<https://pubmed.ncbi.nlm.nih.gov/33716331/> : Infection fatality rate of COVID-19 inferred from seroprevalence data, John P A Ioannidis

Global perspective of COVID-19 epidemiology for a full-cycle pandemic, by John P. A. Ioannidis

### **Kinderen en natuurlijke groepsimmunititeit**

8. Eberhardt CS, Siegrist C-A. Is there a role for childhood vaccination against COVID-19? *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2021; **32**(1): 9-16.

9. Bhopal, S. S., Bagaria, J., Olabi, B., & Bhopal, R. (2021). Children and young people remain at low risk of COVID-19 mortality. *The Lancet. Child & adolescent health*.

### **Over Informed Consent en vrije keuze**

10. Cardozo, T., & Veazey, R. (2021). Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. *Int J Clin Pract*, *75*(3), e13795.

### **Over de inefficiëntie huidige vaccins**

11. Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., . . . Balazs, A. B. (2021). Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell*.

12. Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z.,

Gazumyan, A., Cipolla, M., Luchsinger, L., Hillyer, C. D., Caskey, M., ... Bieniasz, P. D. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *ELife*, 9.

13) Greaney et al. (2021), Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. *bioRxiv* 2020.1231.41.5021

14) Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., Gilchuk, P., Zost, S. J., Tahan, S., Droit, L., Turner, J. S., Kim, W., Schmitz, A. J., Thapa, M., Wang, D., ... Diamond, M. S. (2021). Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nature Medicine*.

15) Andreano, E., & Rappuoli, R. (2021). SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. *Nature medicine*, 27(5), 759-761.

16) McEwen, A. E., Cohen, S., Bryson-Cahn, C., Liu, C., Pergam, S. A., Lynch, J., . . . Roychoudhury, P. (2021). Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State.

17) Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nature medicine*.

### **Over de grotere efficiëntie van een natuurlijke immuniteit**

18) Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., . . . Dong, T. (2020). Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature immunology*, 21(11), 1336-1345.

19) Wang, Z., Yang, X., Zhong, J., Zhou, Y., Tang, Z., Zhou, H., . . . Ran, P. (2021). Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. *Nature Communications*, 12(1), 1724.

20) Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., . . . Buggert, M. (2020). Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*, 183(1), 158.

21) Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., . . . Ismail, S. A. (2021). T cell response to SARS-CoV-2 infection in humans: A systematic review. *PLoS ONE*, 16(1),

22) Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., . . . Ellebedy, A. H. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature*.

### **Zware bijwerkingen als myo- en pericarditis bij jongeren na vaccinatie mRNA covid- vaccin**

23) Marshall, M., Ferguson, I. D., Lewis, P., Jaggi, P., Gagliardo, C., Collins, J. S., . . . Guzman-Cottrill, J. A. (2021). Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics*.

24) Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. *The Journal of pediatrics*, S0022-3476(0021)00617-X.

25) Schauer, J., Buddhé, S., Colyer, J., Sagiv, E., Law, Y., Chikkabyrappa, S. M., & Portman, M. A. Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents. *The Journal of pediatrics*.

### **Verkeerdelijke her-programmatie van het immuunsysteem door vaccinatie met een mRNA covid-19 vaccin**

26) Föhse, F. K., Geckin, B., Overheul, G. J., van de Maat, J., Kilic, G., Bulut, O., . . . Netea, M. G. (2021). The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses. *medRxiv*, 2021

### **Over het ontstaan van ADE (Antibody Dependent Enhancement) -een overreactie van het immuunsysteem - na vaccinatie met het covid- 19 mRNA- vaccin**

27) Valinciute-Jankauskiene, A., & Kubiliene, L. (2021). Adverse Drug Reaction Reporting by Patients in 12 European Countries. *International journal of environmental research and public health*, 18(4), 1507.

28)Cardozo, T., & Veazey, R. (2020). Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease. *International Journal of Clinical Practice*, e13795.

29)Cloutier, M., Nandi, M., Ihsan, A. U., Chamard, H. A., Ilangumaran, S., & Ramanathan, S. (2020). ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. *Cytokine*, 136.

30)Tetro, J. A. (2020). Is COVID-19 receiving ADE from other coronaviruses? *Microbes and Infection*, 22(2), 72–73.

### **Toename zien van het aantal hospitalisaties door RSV en andere infecties door overdreven hygiënische maatregelen**

31) <https://emergency.cdc.gov/han/2021/han00443.asp>

32) Agha, R., & Avner, J. R. (2021). Delayed Seasonal RSV Surge Observed During the COVID-19 Pandemic. *Pediatrics*.

33) <https://www.independent.co.uk/news/world/americas/covid-children-cdc-advisory-rsv-b1882773.html>

34) <https://www.wsj.com/articles/post-covid-19-world-risks-having-to-pay-off-immunity-debt-11624863679>

35) Lu, D. (2021). Children's immunity at risk. *New scientist* (1971), 250(3332), 8-9.

36) <https://www.hln.be/medisch/stijging-ziekenhuisopnames-nieuw-zeelandse-kindjes-door-coronamaatregelen~aeb96eae/>

### **Over de inefficiëntie van de sanitaire maatregelene versus de immens zware sociaal- economische 'collaterale' die deze hebben veroorzaakt**

37. Pannus, P., Neven, K. Y., De Craeye, S., Heyndrickx, L., Kerckhove, S. V., Georges, D., . . . Marchant, A. (2021). Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes. medRxiv, 2021.2006.2008.21258366.
38. Clark, S. A., Clark, L. E., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., . . . Abraham, J. (2021). SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell.
39. Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., . . . Snell, G. (2021). Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184(5), 1171-1187.e1120.
40. Olliaro, P., Torreele, E., & Vaillant, M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. The Lancet Microbe.
41. Andreano, E., & Rappuoli, R. (2021). SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nature medicine, 27(5), 759-761.
42. Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., . . . Diamond, M. S. (2021). Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature medicine.
43. Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., . . . Balazs, A. B. (2021). Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell.
44. McCallum, M., Bassi, J., Marco, A., Chen, A., Walls, A. C., Iulio, J. D., . . . Veesler, D. (2021). SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv.
45. McEwen, A. E., Cohen, S., Bryson-Cahn, C., Liu, C., Pergam, S. A., Lynch, J., . . . Roychoudhury, P. (2021). Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. medRxiv, 2021.2005.2023.21257679.
46. Sharma, P., Mishra, S., Basu, S., Tanwar, N., & Kumar, R. (2021). Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India. medRxiv, 2021.2006.2007.21258447.
47. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nature medicine.

<https://clinicaltrials.gov/ct2/show/NCT04368728>

veiligheid van de vaccins niet gegarandeerd

1) <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty#overview-section>

2) [https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines\\_en.pdf](https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines_en.pdf)





[vaccines/?utm\\_source=salsa&eType=EmailBlastContent&eid=5920171b-ed50-4279-8c4c-50624ba571ad"eid=5920171b-ed50-4279-8c4c-50624ba571ad](https://www.youtube.com/watch?v=IkGB1-YFn1Q)

13) <https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) HYPERLINK

<https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

<https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)app=desktop" HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) HYPERLINK

<https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

<https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)app=desktop" HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) HYPERLINK

<https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) HYPERLINK

<https://www.youtube.com/watch?v=IkGB1-YFn1Q> HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)app=desktop" HYPERLINK

["https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=IkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop)app=desktop" HYPERLINK



["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q"](https://www.youtube.com/watch?v=lkGB1-YFn1Q) HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) & HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) app=desktop" HYPERLINK

["https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop"](https://www.youtube.com/watch?v=lkGB1-YFn1Q&fbclid=IwAR1ADeu7tOScDNX8cbKSskCvp0oFpf--7dsfwiW9VKPuyLYvBWugN4Wwy1w&app=desktop) app=desktop

14)

[https://www.jimmunol.org/content/181/9/6337?fbclid=IwAR25uihPEeGLV0drvSOXx\\_NVHIRwZHAKHImKRQxe3Wuiz6Qo6biDWGCKaik](https://www.jimmunol.org/content/181/9/6337?fbclid=IwAR25uihPEeGLV0drvSOXx_NVHIRwZHAKHImKRQxe3Wuiz6Qo6biDWGCKaik)

15)

[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/?fbclid=IwAR36aFqAit8Mr9dlrZ7Ncp30jyihL-gJ4ATEB\\_q\\_tNTxKNrJuvDPdVdt0](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/?fbclid=IwAR36aFqAit8Mr9dlrZ7Ncp30jyihL-gJ4ATEB_q_tNTxKNrJuvDPdVdt0)

16) <https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijcp.13795>

18) [https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa) HYPERLINK "https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-

[https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) HYPERLINK "https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\_source=salsa HYPERLINK

["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) & HYPERLINK "https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-

[priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) eType=EmailBlastContent HYPERLINK

["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) & HYPERLINK "https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-

[priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b" HYPERLINK

["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) HYPERLINK



[priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b)"eType=EmailBlastContent HYPERLINK

["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b)& HYPERLINK ["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b) HYPERLINK

["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b)eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b" HYPERLINK

["https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm\\_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b"](https://childrenshealthdefense.org/defender/pfizer-covid-vaccine-trial-pathogenic-priming/?utm_source=salsa&eType=EmailBlastContent&eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b)eId=2acac1ba-deb1-48c6-a26a-c1d3c83ef29b

20) <https://www.biorxiv.org/content/10.1101/2020.12.12.422516v1>

21) <https://www.sciencemag.org/news/2020/12/coronavirus-may-sometimes-slip-its-genetic-material-human-chromosomes-what-does-mean>

22) <https://www.fda.gov/media/143557/>

23) <https://www.fda.gov/media/139638/download>

24) <https://www.fda.gov/media/144434/download#page=18>

25) [https://www.who.int/bulletin/online\\_first/BLT.20.265892.pdf](https://www.who.int/bulletin/online_first/BLT.20.265892.pdf)

26) [https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl) HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet) HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl) HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)& HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)la=N HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)& HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)cn=2004050732 HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)& HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)table\_name=wet" HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)& HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet) HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl) HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet)& HYPERLINK

["https://www.ejustice.just.fgov.be/cgi\\_loi/change\\_lg.pl?language=nl&la=N&cn=2004050732&table\\_name=wet"](https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2004050732&table_name=wet) HYPERLINK





Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD. Vaccine-induced enhancement of viral infections. *Vaccine*. 2009;27(4):505–512. doi: 10.1016/j.vaccine.2008.10.087. [PMC free article] [PubMed]

Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, Chu SL, Tse J, Guarner J, Zaki SR, Subbarao K, Peiris M, Nal B, Altmeyer R. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγR2b-dependent entry into B cells in vitro. *Vaccine*. 2007;25(4):729–740. doi: 10.1016/j.vaccine.2006.08.011. [PMC free article] [PubMed]

Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F, Dutry I, Callendret B, Escriou N, Altmeyer R, Nal B, Daeron M, Bruzzone R, Peiris JS. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR2b pathway. *J Virol*. 2011;85(20):10582–10597. doi: 10.1128/JVI.00671-11. [PMC free article] [PubMed]

Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YM, Huang JC. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. *Biochem Biophys Res Commun*. 2014;451(2):208–214. doi: 10.1016/j.bbrc.2014.07.090. [PMC free article] [PubMed]

Rosenthal KS, Zimmerman DH. Vaccines: all things considered. *Clin Vaccine Immunol*. 2006;13(8):821–829. doi: 10.1128/CVI.00152-06. [PMC free article] [PubMed]

Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. *J Virol*. 2011;85(23):12201–12215. doi: 10.1128/JVI.06048-11. [PMC free article] [PubMed]

Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. *PLoS ONE*. 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. [PMC free article]

[fiche's van de klinische studie's en de experimentele status van de covid- 19 vaccins](#)

<https://clinicaltrials.gov/ct2/show/NCT04368728>

<https://clinicaltrials.gov/ct2/show/NCT04516746>

<https://clinicaltrials.gov/ct2/show/NCT04368728>

<https://clinicaltrials.gov/ct2/show/NCT04283461>

<https://clinicaltrials.gov/ct2/show/NCT04324606>

## over de VAERS

### Bronnen en referenties:

1. Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep 2021;70:283–288. DOI: <http://dx.doi.org/10.15585/mmwr.mm7008e3>
2. COVID-19 vaccine safety update, Advisory Committee on Immunization Practices (ACIP) January 27, 2021, Tom Shimabukuro, MD, MPH, MBACDC COVID-19 Vaccine Task Force Vaccine Safety Team
3. Search VAERS data: <https://vaers.hhs.gov/data.html>
4. There were a lot of “unknown age” VAERS death reports—sometimes dozens or even hundreds per year. Therefore, 1/3 of the unknown age reports were added to each of the 3 age groups of 0-17, 18-64 and 65+.
5. US Census Bureau data was used for the years 2014-2020. For 2021, the 2020 population estimates were used.
6. 2014: <https://data.census.gov/cedsci/table?q=census%20age%202014-2020> HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>"  
HYPERLINK "<https://data.census.gov/cedsci/table?q=census%20age%202014-2020> HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>"&  
HYPERLINK "<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>" HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>" HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020> HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>"  
HYPERLINK "<https://data.census.gov/cedsci/table?q=census%20age%202014-2020> HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>"&  
HYPERLINK "<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>" HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>"&  
HYPERLINK "<https://data.census.gov/cedsci/table?q=census%20age%202014-2020&tid=ACSST1Y2014.S0101>" HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020> HYPERLINK  
"<https://data.census.gov/cedsci/table?q=census%20age%202014-2020> HYPERLINK







HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK ["https://data.census.gov/cedsci/table?q=population%20by%20age%202015"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015)

HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) & HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) ["tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) & HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK ["https://data.census.gov/cedsci/table?q=population%20by%20age%202015"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015)

HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) & HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) ["tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) ["tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK ["https://data.census.gov/cedsci/table?q=population%20by%20age%202015"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015)

HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) & HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) ["tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) HYPERLINK

["https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101) ["tid=ACSST1Y2015.S0101"](https://data.census.gov/cedsci/table?q=population%20by%20age%202015&tid=ACSST1Y2015.S0101)

8. 2016: <https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016> HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101)

HYPERLINK ["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016) HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) & HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) ["tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) HYP ERLINK ["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016) HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101)

HYPERLINK ["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016) HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) & HYPERLINK

["https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) ["tid=ACSST1Y2016.S0101"](https://data.census.gov/cedsci/table?q=age%20%26%20sex%202016&tid=ACSST1Y2016.S0101) HYPERLINK















16. Minimum recommended vaccines for each age group were divided among the years in the age group to estimate yearly vaccine consumption:

17. Age 0-17: 18 flu shots + 35 other shots = 53 / 18 = 2.94 per year.

18. Age 18-64: 45 yrs, 45 flu shots + 12 more recommended for everyone (18 more for some) = 45 + 12 = 57 / 45 = 1.24 per year.

19. Age 65+: 15 yrs: 15 flu shots + 5 more recommended for all (18 more recommended for some) = 15 + 5 = 20 / 15 = 1.33 per year.

20. CDC's child and adolescent vaccine schedule:

<https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html>

21. CDC's adult vaccine schedule: <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>

22. For COVID-19 vaccines I used the total # administered in each age group and estimated 5% were given in 2020 and 95% were given in 2021. <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic>

<https://www.foxnews.com/media/tucker-carlson-mrna-vaccine-inventor>

<https://www.rockefellerfoundation.org/wp-content/uploads/Annual-Report-2010-1.pdf>

bijwerkingen van vaccinaties bij jongeren

<https://www.nvkp.nl/fileadmin/nvkp/pdf/Dossiers/Coronavirus-COVID-19-dossier.pdf>

[https://ec.europa.eu/commission/presscorner/detail/nl/qanda\\_20\\_2390](https://ec.europa.eu/commission/presscorner/detail/nl/qanda_20_2390)

- 1\* [https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information\\_en.pdfOpen](https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdfOpen)
- 2\* <https://www.reuters.com/world/middle-east/israel-sees-probable-link-between-pfizer-vaccine-small-number-myocarditis-cases-2021-06-01/>
- 3\* <https://www.dailymail.co.uk/news/article-9720151/FDA-add-warning-Pfizer-Moderna-vaccines.html>
- 4\* <https://www.lareb.nl/news/ontsteking-van-de-hartspier-en-hartzakje-bijwerking-van-pfizer-en-moderna-vaccin>
- 5\* <https://childrenshealthdefense.org/defender/dr-mike-yeardon-rfk-jr-the-defender-podcast-safety-mrna-vaccine-technology/>
- 6\* <https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-who-estimates-covid-19-boosters-needed-yearly-most-vulnerable-2021-06-24/>
- 7\* [https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(21\)00069-0/fulltext](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00069-0/fulltext)
- 8\* [https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information\\_en.pdfOpen](https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdfOpen)
- 9\* [https://www.who.int/bulletin/online\\_first/BLT.20.265892.pdf](https://www.who.int/bulletin/online_first/BLT.20.265892.pdf)
- 10\* <https://www.rivm.nl/coronavirus-covid-19/kinderen>
- 11\* [De grafiek geeft de leeftijdscategorie 10 t/m > 19 jaar aan.](https://www.rivm.nl/coronavirus-covid-19/grafieken)
- 12\* [https://nl.wikipedia.org/wiki/Virus\\_\(biologie\)](https://nl.wikipedia.org/wiki/Virus_(biologie))

<https://factcheckvaccine.com/2021/06/who-children-should-not-be-vaccinated-for-the-moment-june-22-2021/>

<https://www.mdpi.com/2076-393X/9/7/693> - The Safety of COVID-19 Vaccinations—We Should Rethink the Policy

by Harald Walach 1,2,3,\* ,Rainer J. Klement 4OrcID andWouter Aukema 5OrcID

1. Poznan University of the Medical Sciences, Pediatric Hospital, 60-572 Poznan, Poland
2. Department of Psychology, University of Witten/Herdecke, 58448 Witten, Germany
3. Change Health Science Institute, 10178 Berlin, Germany
4. Department of Radiation Oncology, Leopoldina Hospital, 97422 Schweinfurt, Germany
5. Independent Data and Pattern Scientist, Brinkenberweg 1, 7351 BD Hoenderloo, The Netherlands

\*

Author to whom correspondence should be addressed.

<https://vernoncoleman.org/articles/how-many-people-are-vaccines-killing>

<https://stichtingvaccinvrij.nl/wp-content/uploads/2021/06/De-korte-en-langetermijnbijwerkingen-van-de-covidvaccinaties-door-Johan-van-Lier-juni-2021.pdf>

Professor en Nobelprijswinnaar **Luc Montagnier** : covid-vaccin kan leiden tot slopende 'Neurodegeneratieve ziekten' :

<https://scivisionpub.com/pdfs/covid19-rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf>

Meeting CDC 10 juni : VRBPAC-06.10.21-Meeting-Presentation-COVID19-Vaccine-Safety-Updates)

<https://dailyexpose.co.uk/2021/06/24/crimes-against-humanity-uk-government-release-21st-report-on-adverse-reactions-to-the-covid-vaccines/>

SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048) - 2.6.4 Summary of pharmacokinetic study

COVID-19 RNA Based Vaccines and the Risk of Prion Disease

Classen Immunotherapies, Inc., 3637 Rockdale Road, Manchester,

MD 21102, E-mail: [classen@vaccines.net](mailto:classen@vaccines.net).

J. Bart Classen, MD\*

COVID-19 RNA Based Vaccines and the Risk of Prion Disease

Classen Immunotherapies, Inc., 3637 Rockdale Road, Manchester,

MD 21102, E-mail: [classen@vaccines.net](mailto:classen@vaccines.net).

J. Bart Classen, MD\* - Microbiology & Infectious diseases

COVID-19 Vaccine Associated Parkinson's Disease, A Prion Disease Signal

in the UK Yellow Card Adverse Event Database

Classen Immunotherapies, Inc., 3637 Rockdale Road, Manchester,

MD 21102, E-mail: classen@vaccines.net.

J. Bart Classen, MD\* - Journal of Medical - Clinical Research & Reviews

ADE studie

<https://pubmed.ncbi.nlm.nih.gov/16214268/>

Over spike-proteïnen

<https://pubmed.ncbi.nlm.nih.gov/29900602/>

<https://www.embopress.org/doi/full/10.15252/emmm.202114150>

<https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html>

Letter of Support - Robert W Malone, MD, M to Dr.-B-Bridle

Supplementary Appendix to Olliaro P, Torreale E, Vaillant M. COVID-19 vaccine efficacy and (The Lancet)

mail Dr. Fauci NIH-NIAID dd 16 03 2020 over effectiviteit hydroxychloroquine

Supplementary Appendix to Olliaro P, Torreale E, Vaillant M. COVID-19 vaccine efficacy and (The Lancet)

NIH-Moderna-Confidential-Agreements

Pfizer-bio-distribution-confidential-document-translated-to-english -Summary of pharmacokinetic study

Inzake de mondmaskers

1\* advies van de WHO van 5 juni 2020 *“However, taking into account the available studies evaluating pre- and asymptomatic transmission, a growing compendium of observational evidence on the use of masks by the general public in several countries, individual values and preferences, as well as the difficulty of physical distancing in many contexts, WHO has updated its guidance to advise that to prevent COVID-19 transmission effectively in areas of community transmission, governments should*

*encourage the general public to wear masks in specific situations and settings as part of a comprehensive approach to suppress SARS-CoV-2 transmission.”*

2\* advies van de WHO van 5 juni 2020 *“Results from cluster randomized controlled trials on the use of masks among young adults living in university residences in the United States of America indicate that face masks may reduce the rate of influenza-like illness, but showed no impact on risk of laboratory-confirmed influenza.(62, 63) At present, there is no direct evidence (from studies on COVID-19 and in healthy people in the community) on the effectiveness of universal masking of healthy people in the community to prevent infection with respiratory viruses, including COVID-19.”*

3\* advies van de WHO van 5 juni 2020 *“A recent meta-analysis of these observational studies, with the intrinsic biases of observational data, showed that neither disposable surgical masks nor reusable 12–16-layer cotton masks were associated with protection of healthy individuals within households and among contacts of cases.”*

<https://www.artsenvoorvrijheid.be/blog/2020/11/14/mondmaskers-geven-wel-hypercapnie-door-dr-hilde-de-smet/>

Dr. Harkinson

[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(17\)30229-1/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30229-1/fulltext)

**Denis G. Rancourt, PhD Researcher, Ontario Civil Liberties Association :**

<https://archive.org/details/covid-censorship-at-research-gate-2/> April 2020 Summary /

<https://muchadoaboutcorona.ca/wp-content/uploads/2020/07/masks-dont-work-rancourt.pdf>

<https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1174-6591> -Mund-Nasen-Schutz in der Öffentlichkeit - Keine Hinweise für eien Wirksamkeit, Ines Kapstein

## **Andere**

FAGG Lijst Bijwerkingen na vaccinatie tegen covid- 19 /verduidelijking rond het melden van bijwerkingen na vaccinatie tegen COVID-19 - AFMPS/FAGG (lijst bijwerkingen FAGG)

Informatie verstrekt onder het gezag van het FAGG/Rechtstreekse mededeling aan de gezondheidszorgbeoefenaars/VAXZEVRIA/COVID-19 Vaccine AstraZeneca: ***Contra-indicatie bij personen met een voorgeschiedenis van capillair leksyndroom (CLS)***

What Ingredients are in the COVID-19 Vaccine? [ct.gov/covidvaccin](https://www.ct.gov/covidvaccin) /DPH

Safety Data Sheet SM-102 Safety (Cayman Chemical)

Pre-vaccination Checklist for covid- 19 vaccines DPH VAMS

SARS-CoV-2-Criminal-Malfeasance-2 - Open Demand Letter (The Canadian Peoples Union NF) to Mr. Lametti